Benztropine Mesylate
The mesylate salt form of benztropine, an anticholinergic drug used to relieve Parkinson's symptoms and drug-induced movement disorders. It helps reduce tremor, muscle stiffness, and involuntary movements by blocking certain nerve signals. Common side effects include dry mouth, blurred vision, and constipation.
Berat Molekul
403,5000 g/mol
TPSA
75,20 Ų
Area Terapeutik
Mekanisme Kerja
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2.CS(=O)(=O)O
InChI
InChI=1S/C21H25NO.CH4O3S/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17;1-5(2,3)4/h2-11,18-21H,12-15H2,1H3;1H3,(H,2,3,4)/t18-,19+,20+;
Molecular Formula
C22H29NO4S
HBD / HBA
1 / 5
Ikatan yang Dapat Dirotasi
4
Atom Berat
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
The mesylate salt form of benztropine, an anticholinergic drug used to relieve Parkinson's symptoms and drug-induced movement disorders. It helps reduce tremor, muscle stiffness, and involuntary movements by blocking certain nerve signals. Common side effects include dry mouth, blurred vision, and constipation.
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Yes, Benztropine Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200383. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 238053. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="benztropine-mesylate"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/benztropine-mesylate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/benztropine-mesylate/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/benztropine-mesylate/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="benztropine-mesylate"></drugfyi-drug>